Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
This article was originally published in PharmAsia News
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
You may also be interested in...
Start-up Hua Medicine says IND filing time using China’s green channel shortened the review process at the provincial level.
DIA President Ling Su On Bridging Gaps In China On The Road To Innovation: An Interview With PharmAsia News
DIA President Ling Su has a unique perspective on the Chinese market, having served in senior R&D positions with industry – most recently at Novartis China – and as a regulator, including stints in China’s Ministry of Health and as a visiting scientist with U.S. FDA. He recently sat down with PharmAsia News to discuss innovation and the evolution taking place in China.
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.